Anti-fibrotic mechanisms of angiotensin AT

Animals Fibrosis / chemically induced Heart Diseases / prevention & control Humans Kidney Diseases / prevention & control Receptor, Angiotensin, Type 2 / agonists
angiotensin angiotensin AT2-receptor fibrosis fibrotic disease

Journal

Acta physiologica (Oxford, England)
ISSN: 1748-1716
Titre abrégé: Acta Physiol (Oxf)
Pays: England
ID NLM: 101262545

Informations de publication

Date de publication:
09 2019
Historique:
received: 10 12 2018
revised: 23 03 2019
accepted: 02 04 2019
pubmed: 9 4 2019
medline: 1 9 2020
entrez: 9 4 2019
Statut: ppublish

Résumé

The angiotensin AT

Identifiants

DOI: 10.1111/apha.13280 PMID: 30957953
pubmed: 30957953
doi: 10.1111/apha.13280
doi:

Substances chimiques

Receptor, Angiotensin, Type 2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13280

Subventions

Organisme : Novo Nordisk Foundation
ID : 6239
Pays : International
Organisme : Det Frie Forskningsråd
ID : 4004-00485B
Pays : International

Informations de copyright

© 2019 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Auteurs

Colin Sumners (C)

Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida.

Antonio Augusto Peluso (AA)

IMM - Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.

Andreas Houe Haugaard (AH)

IMM - Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.

Jesper Bork Bertelsen (JB)

IMM - Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.

Ulrike Muscha Steckelings (UM)

IMM - Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.
ORCID: 0000-0002-5430-4275

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Anti-fibrotic mechanisms of angiotensin AT
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Anti-fibrotic mechanisms of angiotensin AT
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Anti-fibrotic mechanisms of angiotensin AT
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Anti-fibrotic mechanisms of angiotensin AT
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Anti-fibrotic mechanisms of angiotensin AT
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteurs aux angiotensines › Récepteur de type 2 à l'angiotensine-II › Anti-fibrotic mechanisms of angiotensin AT